Following is a summary of the Brighter Group’s current operational activities.
Brighter is optimizing its team within several areas, including sales & go-to-market, data science, regulatory, R&D and business development, in Sweden, GCC and SEA. The company is advancing the work to establish new strategic and commercial partnerships to support commercialization. All the teams are vigorously pursuing sales opportunities on the markets in which our solutions are already available or are currently undergoing market approval processes. Main priority is go-to-market and revenue generation.
The Actiste service (direct B2C e-Commerce offering) went live in Sweden in May 2020. The primary objective with this launch is to gain valuable real-world user data and additional proof points from live patients to support Brighter’s ongoing commercialization efforts in other markets. Brighter is also pursuing additional Swedish sales opportunities in terms of co-operations with health clinics and public healthcare establishments, as well as through the ongoing development of Diabetesdoktorn in partnership with the digital healthcare provider Accumbo. Furthermore, we are well on our way with establishing commercial partnerships in Southeast Asia and the Middle East. In July 2020, we initiated a partnership with the Provincial Government of West Java in Indonesia. Within the framework of the collaboration Brighter will deliver 100 Actiste subscriptions and support the training of healthcare staff at local hospitals in administering Actiste.
Ongoing Actiste market approval processes:
United Arab Emirates, Saudi Arabia, Indonesia, Thailand, Singapore, Malaysia
Camanio is currently focusing on the commercialization of its recently launched SmartCare platform – a solution supporting the transition to a completely digital home care, enabling caregivers to tailor the digital ecosystem at home. In May, Camanio also launched “Trygga Möten” – a digital video conferencing service specifically designed for use in the Swedish elderly care sector.
The company is well established on the Swedish healthcare market and has since its foundation sold products to more than 50% of the municipalities in Sweden.
Nectarine Health, introducing a highly intelligent AI platform assisting senior living and independent living facilities, is live with its first-generation solution for professional use.
The company is currently developing a direct to consumer offering, with its generation 2 solution, which will be Nectarine’s main focus going forward. Expected to be ready for launch in 2021.
Research & Development, IP
Brighter is continuously working on expanding its IP and product portfolio. On July 7, 2020, the company was proud to announce a whole new device: Actiste® Mini, which has already obtained CE marking. The device will be a key element in a new service currently being developed by Brighter.
The company currently has 27 granted patents and 38 patents pending.
Global scope of protection
EPO, US, SE, GB, DE, FR, JP, CH, NL, BR, ID, IN, TR, PL, MY, MX, SG, KR, VN, TH
For further information, please contact:
Henrik Norström, CEO
+46 733 40 30 45
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, firstname.lastname@example.org, www.eminova.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.